← Association for Accessible Medicines
FDANonrulemakingFDA-2020-N-2252

Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act; Public Meeting; Request for Comments

RIN
—
Last modified
May 26, 2022
Comment window
closed 1527d ago
Association for Accessible Medicines filings
1

Activity

Association for Accessible Medicines filed 1 comment on this docket between Feb 2, 2021 and Feb 2, 2021. 0 other organizations filed here. The comment window closed 1527d ago.

What Association for Accessible Medicines filed (1)

Feb 2, 2021· Comment from The Association for Accessible Medicines (AAM)· FDA-2020-N-2252-0003

Comments from The Association for Accessible Medicines (AAM) Biosimilar's Council on behalf of our member companies, regarding the Interim Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act; Public Meeting.

View on regulations.gov →

Abstract

No abstract recorded.

View on regulations.gov →

Co-filers (0)

See everyone who commented →